Cargando…
Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
AIM: To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization (TACE) treatment for intermediate hepatocellular carcinoma (HCC). METHODS: Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B (BCLC-B)] HCC who were treated with sorafenib plus...
Autores principales: | Lei, Xue-Fen, Ke, Yang, Bao, Tian-Hao, Tang, Hao-Ran, Wu, Xue-Song, Shi, Zhi-Tian, Lin, Jie, Zhang, Zhi-Xian, Gu, Hou, Wang, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955731/ https://www.ncbi.nlm.nih.gov/pubmed/29774219 http://dx.doi.org/10.12998/wjcc.v6.i5.74 |
Ejemplares similares
-
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018) -
Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization
por: Rattanasupar, Attapon, et al.
Publicado: (2022) -
Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer
por: Bian, Li-Fang, et al.
Publicado: (2020) -
Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020) -
Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma
por: Chen, Ming-Yu, et al.
Publicado: (2020)